Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention
Department of Radiation Oncology; Department of Cancer Biology; Program in Molecular Medicine; Department of Cell Biology; Department of Surgery; School of Medicine
Adenocarcinoma; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Tolerance; Risk Factors; Treatment Outcome
Male Urogenital Diseases | Neoplasms | Oncology | Radiology | Urology
Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.
DOI of Published Version
Expert Rev Anticancer Ther. 2008 Jun;8(6):967-74. doi: 10.1586/14737126.96.36.1997. Link to article on publisher's site
Expert review of anticancer therapy
Fitzgerald, Thomas J.; Wang, Tao; Goel, Hira Lal; Huang, Jiayi; Stein, Gary S.; Lian, Jane B.; Davis, Roger J.; Doxsey, Stephen J.; Balaji, Kethandapatti C.; Aronowitz, Jesse N.; and Languino, Lucia R., "Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention" (2008). University of Massachusetts Medical School. Senior Scholars Program. Paper 186.